CRDO
Credo Technology Group Holding Ltd
CRDO has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
CRDO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CRDO's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CRDO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $140 | — |
| Current | 49x | $140 | — |
| Cheap | 75x | $212 | +52% |
| Fair | 124x | $353 | +152% |
| Expensive | 395x | $1,122 | +703% |
Historical ranges are pointers, not guarantees.
CRDO's PE is in its cheap range at 49x. If earnings grow as analysts expect, today's price would be 17x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over CRDO in the historical PE scenario, which offers more potential upside but is not a forecast.
CRDO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
CRDO has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CRDO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.35 | +194% |
| Q3 2026 | $2.84 | +312% |
| Q2 2026 | $2.51 | +766% |
| Q1 2026 | $1.82 | +18100% |
| Q4 2025 | $1.16 | +$1.31 |
| Q3 2025 | $0.69 | +$0.85 |
| Q2 2025 | $0.29 | +$0.47 |
| Q1 2025 | $0.01 | +$0.24 |
| Q4 2024 | -$0.15 | +$0.06 |
CRDO's earnings per share have climbed steadily: $2.84 over the past year, about four times what it earned the year before, and higher year over year for nine quarters in a row.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
CRDO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $479M | +115% |
| Q2 2026 | $437M | +157% |
| Q1 2026 | $407M | +201% |
| Q4 2025 | $268M | +272% |
| Q3 2025 | $223.1M | +274% |
| Q2 2025 | $170M | +180% |
| Q1 2025 | $135M | +154% |
| Q4 2024 | $72M | +64% |
CRDO has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 25% | -2 points |
| Q2 2026 | 36% | +16 points |
| Q1 2026 | 37% | +17 points |
| Q4 2025 | 29% | +41 points |
| Q3 2025 | 27% | +51 points |
| Q2 2025 | 20% | +33 points |
| Q1 2025 | 19% | +31 points |
| Q4 2024 | -12% | +8.5 points |
CRDO's operating margin was 25% last quarter, down 2 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CRDO on profitability, with a higher operating margin.
CRDO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $82.9M | +62% |
| Q2 2026 | $177.5M | +228% |
| Q1 2026 | $139.7M | +$140.1M |
| Q4 2025 | $38.5M | +$50.1M |
| Q3 2025 | $51.3M | +$64.4M |
| Q2 2025 | $54.2M | +5531% |
| Q1 2025 | -$383K | +$5.8M |
| Q4 2024 | -$11.7M | -494% |
CRDO has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CRDO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +6.1M shares |
| 1 year | +5.3% | +9.8M shares |
| 3 years | +30% | +45.1M shares |
| 5 years | +39% | +54.4M shares |
CRDO has 194M diluted shares, up 5.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $22.9M |
| Q3 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CRDO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CRDO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -2.4x | Net Cash |
| Q1 2026 | -3.5x | Net Cash |
| Q4 2025 | -2.5x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -4.0x | Net Cash |
| Q1 2025 | -22.2x | Net Cash |
CRDO has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CRDO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 9.2 | Oversold |
CRDO's weekly RSI is 42 (neutral) and its Stochastic is 9 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CRDO PE vs Technology Sector
| Metric | CRDO | Sector median | Relative |
|---|---|---|---|
| PE | 49x | 28x | 77% above |
| PE % | 1 | 48 | 47 pts below |
CRDO is trading at 49x earnings, a 77% premium to the Technology sector's median of 28x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over CRDO on valuation relative to its sector.
CRDO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $171.8 | 19% below |
| 20 week MA | $199.0 | 30% below |
| 50 week MA | $174.7 | 20% below |
| 100 week MA | $134.3 | 4.1% above |
| 200 week MA | $78.2 | 79% above |
CRDO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CRDO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $11.2 | $13.0 | +16% |
| 2023 | $13.0 | $19.5 | +50% |
| 2024 | $19.5 | $69.3 | +256% |
| 2025 | $69.3 | $144.8 | +109% |
| 2026 YTD | $144.8 | $139.8 | -3.5% |
CRDO has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.